Patent · US Active

Integrin inhibitors for the treatment of eye diseases

US7645736B2 · kind B2 · utility

16Cited by

3References

23Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Hans-Markus Bender · Birkenfeld, DE
Jutta Haunschild · Birkenfeld, DE
Ulrich Lang · San Francisco, US
Matthias Wiesner · Seeheim-Jugenheim, DE
Martin Friedlander · Del Mar, US

Key dates

Filing date	Aug 28, 2006
Grant date	Jan 12, 2010
Priority date	—
Expiry date	Aug 7, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P27/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods for the treatment of a disease of the eye of a patient comprising injecting into the vitreous body of the eye a composition comprising a therapeutically effective amount of an αvβ3 and/or αvβ5 inhibitor sufficient to inhibit angiogenesis and inhibit neovascularization in the treated eye. The αvβ3 and/or αvβ5 inhibitor being a compound of formula II:as defined herein or a physiologically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.